HIV Drug Medicine Market Size, Demand & Opportunity Analysis By Type (generic medicine,Multi class combination products, Nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Entry inhibitors – CCR5 co-receptor antagonist, Fusion inhibitors, Protease inhibitors, HIV integrase strand transfer inhibitors)

Share This Post

Research Nester has recently announced new market demand assessment research titled HIV Drug / Medicine Market – Global Demand Analysis & Opportunity Outlook 2021. The global market study provides a granular data and in-depth analysis on the current and future market situations that are crucial for the existing &new players in the market. The industry research is based on key factors like demand & supply analysis, commercial activities, research investments, pricing analysis, government initiatives & guidelines, driving forces in the market, roadblocks and segmentation based on the product viability.

Several government initiatives have been started and awareness programs are entertained in order to minimize the burden of HIV across the globe.

Improvements in medicinal therapies like antiretroviral therapy (ART) which are also affordable for the patients suffering from HIV helps in the overall care and also increasing life expectancy of the patients.

25 antivirals, 16 vaccines and 3 gene therapies have been introduced in the U.S. in 2014 to improve treatment facilities with better and effective cure. Several drugs have been recently licensed for the treatment of HIV-1 infected patients. These new drugs include CCR5 co-receptor antagonist which is using for the patients those have developed resistance from previous drugs and therapies. New developments and introduction of effective and affordable therapies is expected to expand the demand for HIV drugs over the forecast period i.e. 2015-2023.

The HIV Drug market is expected to expand at a CAGR of 5.93% during the forecast period 2015-2023. The HIV Drug market is expected to reach USD 38.01 Billion by 2023 from USD 26.9 Billion in 2015. The U.S. is expected to showcase a lucrative growth in HIV Drug market in the forecast period and HIV Drug market is expected to reach USD 2.2 Billion during the forecast period i.e. 2015-2023 in the region. The HIV Drug market is expected to expand at a rapid pace over the forecast period 2015-2023 due to introduction of new and effective drugs with less side-effect which will spur the demand for HIV drugs across the globe.

Lack of awareness in under developed nations towards protected sex is likely to further raise the population suffering from HIV which is further believed to increase the growth of HIV drug market across the globe during the forecast period 2015-2023. Advancement in healthcare and drug technology due to huge funding in Research and Development sector would help the companies to develop more effective drugs to restrict the dysfunctions and loss of immunity in the human body and is expected to grow the demand of HIV drug and further enforce the market of HIV drug globally. Further, governmental initiatives and rising awareness towards HIV and its carrier is anticipated to propel the demand for HIV drug market over the forecast period 2015-2023 globally. Apart from this, huge funding from the governmental authorities to provide better facilities and cure at affordable cost will make buyers to adopt the precautions related to HIV which is expected to propel further expand the demand of HIV drug market globally.

Availability of Anti-retroviral Therapy (ART) with efficient fixed-dose combination reduces the burden of taking excess of pills to keep the infection inactive on the human body which helps the patients to opt these therapies with minimized number of dose. These therapies are expected to grow the demand of HIV Drug over the forecast period i.e. 2015-2023.

  • Multi class combination products, Nucleoside reverse transcriptase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Entry inhibitors – CCR5 co-receptor antagonist, Fusion inhibitors, Protease inhibitors, HIV integrase strand transfer inhibitors

Analysis By Drugs Type

  • Multi class combination products
  • Nucleoside reverse transcriptase inhibitors
  • Non-nucleoside reverse transcriptase inhibitors
  • Entry inhibitors – CCR5 co-receptor antagonist
  • Fusion inhibitors
  • Protease inhibitors
  • HIV integrase strand transfer inhibitors

Key Players

The key developers of HIV Drugs across the globe as follows:

    • GlaxoSmithKline
    • Company Overview
    • Key Product Offerings
    • Business Strategy
    • SWOT Analysis
    • Financials
    • Johnson and Johnson
    • Merck
    • Hetero Drugs
    • Gilead Sciences

Regions Studied:

  • North America (United States / U.S., Canada)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Western and Eastern Europe (Germany, Italy, Spain, France, U.K, Benelux, Hungary, Rest Of Western Europe, Russia, Poland, Rest of Eastern Europe)
  • Asia-Pacific (China, India, Singapore, Japan, Australia & New Zealand & Rest of Asia)
  • Rest of World

To know more on coverage, click on the link below:-


Contact Us:
Ajay Daniel
Email: ajay.daniel@researchnester.com
Phone : U.S. +1 646 586 9123
U.K. +44 203 608 5919


Leave a Reply